Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities

Ibrutinib revolutionized the CLL treatment approach and prognosis demonstrating its efficacy and safety even at extended follow-up. During the last few years, several next-generation inhibitors have been developed to overcome the occurrence of toxicity or resistance in patients on continuous treatme...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancers 2023-02, Vol.15 (5), p.1504
Hauptverfasser:	Frustaci, Anna Maria, Deodato, Marina, Zamprogna, Giulia, Cairoli, Roberto, Montillo, Marco, Tedeschi, Alessandra
Format:	Artikel
Sprache:	eng
Schlagworte:	Antimitotic agents Antineoplastic agents CD20 antigen Chronic lymphocytic leukemia Clinical trials Drug dosages Drug therapy Kinases Medical prognosis Monoclonal antibodies Mutation Patients Pharmaceutical research Pharmacokinetics Response rates Review Risk groups Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!